| Identification | Back Directory | [Name]
Talaporfin sodium | [CAS]
220201-34-3 | [Synonyms]
NPe6
ME2906
D01985
Laserphyrin
Taporfin sodiuM
Laserphyrin (tn)
Talaporfin sodium
Talaporfin sodiuM salt
Talaporfin sodium (jan/usan)
Mono-L-Aspartyl Chlorin e6 Tetrasodium Salt (NPe6)
N-[2-[(7S,8S)-3-Carboxy-7-(2-carboxyethyl)-13-ethenyl-18-ethyl-7,8-dihydro-2,8,12,17-tetraMethyl-21H
TetrasodiuM (2S)-2-((((7S,8S)-3-carboxylato-7-(2-carboxylatoethyl)-13-ethenyl-18-ethyl-2,8,12,17-tet
N-[2-[(7S,8S)-3-Carboxy-7-(2-carboxyethyl)-13-ethenyl-18-ethyl-7,8-dihydro-2,8,12,17-tetraMethyl-21H,23H-porphin-5-yl]acetyl]-L-aspartic acid sodiuM salt
Tetrasodium (2S)-2-((((7S,8S)-3-carboxylato-7-(2-carboxylatoethyl)-13-ethenyl-18-ethyl-2,8,12,17-tetramethyl-7,8-dihydroporphyrin-5-yl)acetyl)amino)butanedioate | [Molecular Formula]
C38H37N5O9.4Na | [MOL File]
220201-34-3.mol | [Molecular Weight]
799.696 |
| Chemical Properties | Back Directory | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO:2.0(Max Conc. mg/mL);2.5(Max Conc. mM)
Water:50.0(Max Conc. mg/mL);62.52(Max Conc. mM) | [form ]
A solid | [color ]
Purple to black | [SMILES]
O=C(C[C@H](NC(C/C1=C2[C@@H](CCC(O[Na])=O)[C@H](C)C(/C=C3N/C(C(C=C)=C\3C)=C\C4=N/C(C(CC)=C4C)=C\C5=C(C(C(O[Na])=O)=C1N5)C)=N\2)=O)C(O[Na])=O)O[Na] |
| Hazard Information | Back Directory | [Uses]
Talaporfin sodium is photosensitizer for use in photodynamic therapy to destroy tumor tissue.
| [in vivo]
Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs) [1].
Labeling in vivo:
1. Use the rat brain tumor model produced by the inoculation of resuspended tumor cells into the frontal rat brain. Feed animals according to your normal protocol.
2. Intravenous injection of 5 mg/kg body weight talaporfin sodium, the concentration of the talaporfin sodium is 5 mg/1 ml 0.9% saline.
3. For the control group, intraperitoneal injection of 100 mg/kg body weight 5-ALA, the concentration of the 5-ALA is 20 mg/1 ml 0.9% saline.
4. Obtain the tissue samples corresponding to the tumor (or edema) brain tissue with 5 mm thickness.
5. The samples are well homogenized with 1 ml of 100% dimethyl sulfoxide (DMSO) and the 100 ul aliquots of the supernatant are put into each well of a 96-well plate.
6. Measure the relative fluorescence intensities of the samples by using a microplate readerin emission wavelength of 670 ±10 nm. The relative fluorescence intensities of the samples (a.u.) were normalized to the relative fluorescence intensities per 1 g-weight of the samples (a.u.).
| Animal Model: | Rat brain tumor model[1] | | Dosage: | 5 mg/kg | | Administration: | Intravenous injection | | Result: | Showed high fluorescence intensity and retention in brain tumor differentiated from vasogenic edema. |
|
|
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
|